Search clinical trials for: pomalidomide (CC-4047
Total 1080 results
-
Milton S. Hershey Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
CelgeneCompletedPrimary Myelofibrosis | MPN-associated MyelofibrosisUnited States, Netherlands, France, Australia, Italy, United Kingdom, Canada, Germany, China, Spain, Belgium, Austria, Poland, Sweden, Japan, Russian Federation
-
CelgeneTerminatedSystemic Sclerosis | Scleroderma, Systemic | Systemic Scleroderma | Interstitial Lung Disease | Sclerosis, SystemicUnited States, Spain, France, Australia, Italy, Switzerland, Germany, Poland, United Kingdom, Russian Federation
-
Stanford UniversityCelgene CorporationWithdrawnPulmonary FibrosisUnited States
-
CelgeneCompletedMultiple MyelomaCanada, Denmark, Australia, Belgium, France, Germany, Italy, Netherlands, Russian Federation, Spain, Sweden, Switzerland, United Kingdom, Czechia, Greece
-
CelgeneCompletedMultiple MyelomaBelgium, United Kingdom, Italy, Germany, Sweden, Denmark, Norway, Spain
-
CelgeneCompletedAnemia, Sickle CellUnited States
-
Yale UniversityCelgene CorporationCompletedMultiple MyelomaUnited States
-
University of ArkansasCelgeneCompletedMultiple MyelomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedChronic Myeloproliferative Disorders | Secondary MyelofibrosisUnited States
-
CelgeneTerminatedSoft Tissue SarcomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
University of UlmActive, not recruitingPrimary Myelofibrosis | Secondary Myelofibrosis | Post-PV MF | PMF | SMF | Post-ET MFGermany
-
The Cleveland ClinicCompletedHereditary Hemorrhagic Telangiectasia | Idiopathic Vascular EctasiaUnited States
-
CelgeneCompleted
-
Washington University School of MedicineCompleted
-
Celgene CorporationCompletedSafety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)Prostate CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Waldenstrom Macroglobulinemia | Refractory Waldenstrom MacroglobulinemiaUnited States
-
National Cancer Institute (NCI)CompletedNeurofibromatosis Type 1 | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Visual Pathway GliomaUnited States
-
CelgeneCompletedCentral Nervous System Neoplasms | MedulloblastomaUnited States, Italy, France, Spain, United Kingdom
-
CelgeneCompletedMultiple MyelomaUnited States, Netherlands, Canada, Belgium, United Kingdom, Australia, Denmark, Germany, Spain, Switzerland, France, Italy, Greece, Russian Federation, Sweden, Czechia
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMultiple Myeloma and Plasma Cell NeoplasmUnited States
-
RenJi HospitalThe First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaboratorsRecruiting
-
University Hospital, LilleCelgene CorporationCompleted
-
CelgeneCompletedMyelofibrosis | Myeloid Metaplasia | Myelofibrosis With Myeloid MetaplasiaUnited States, Italy, United Kingdom, Austria, Spain
-
Steven P. Treon, MD, PhDCelgene CorporationTerminatedWaldenstrom's MacroglobulinemiaUnited States
-
SCRI Development Innovations, LLCCelgene CorporationCompletedPancreatic CancerUnited States
-
OHSU Knight Cancer InstituteSanofi; Oregon Health and Science UniversityActive, not recruitingRefractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaUnited States
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); University of California, Los Angeles; Montefiore... and other collaboratorsActive, not recruitingHuman Immunodeficiency Virus 1 Positive | Skin Kaposi SarcomaUganda, Kenya, Malawi
-
CelgeneMultiple Myeloma Research ConsortiumCompleted
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Nervous System Lymphoma | Recurrent Primary Vitreoretinal DLBCL | Refractory Nervous System Lymphoma | Refractory Primary Vitreoretinal DLBCLUnited States
-
Celgene CorporationCompleted
-
CelgeneCompletedMultiple MyelomaUnited States, Spain, United Kingdom, Italy, Israel, Portugal, Germany, Turkey, Greece, Ireland, Austria, Norway, Netherlands, Denmark, Poland, France, Russian Federation, Canada, Finland, Japan, Puerto Rico, Sweden
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)TerminatedPrimary Systemic Amyloidosis | Light Chain Deposition DiseaseUnited States, Canada
-
CelgeneTerminatedCarcinoma, Small CellUnited States, Canada
-
M.D. Anderson Cancer CenterCelgeneCompleted
-
Criterium, Inc.Celgene Corporation; AmgenTerminated
-
CelgeneActive, not recruitingMultiple MyelomaUnited States, Canada, Japan, Puerto Rico
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRefractory Multiple MyelomaUnited States
-
OncotherapeuticsTerminated
-
Ashraf BadrosMerck Sharp & Dohme LLCTerminatedMultiple MyelomaUnited States
-
CelgeneWithdrawnMultiple MyelomaChina, Australia, United States, Argentina, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Greece, Hungary, India, Ireland, Italy, Japan, Korea, Republic of, Norway, Portugal, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH); AmgenActive, not recruitingPlasma Cell MyelomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaUnited States
-
Cristina GasparettoCelgeneActive, not recruiting
-
University of ChicagoNational Cancer Institute (NCI); Multiple Myeloma Research FoundationRecruitingMultiple MyelomaUnited States, Canada
-
CelgeneCompleted
-
Radboud University Medical CenterNorgineUnknownColorectal NeoplasmsNetherlands, Greece
-
CelgeneActive, not recruitingMultiple MyelomaAustria